Lasa Supergenerics Limited (NSE:LASA)

Market Cap	366.74M -25.6%
Revenue (ttm)	253.41M -82.8%
Net Income	-340.90M
EPS	-6.80
Shares Out	50.10M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	15,181
Open	7.67
Previous Close	7.53
Day's Range	7.28 - 7.67
52-Week Range	5.67 - 14.08
Beta	0.62
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 12, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, s...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 2016
• Employees: 66
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: LASA

Financial Performance

In fiscal year 2026, Lasa Supergenerics's revenue was 253.41 million, a decrease of -82.82% compared to the previous year's 1.47 billion. Losses were -340.90 million, 131.0% more than in 2025.

Data Sources: S&P Global Market Intelligence and Financial Modeling Prep

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Financial Modeling Prep.

Last checked:

Jul 13, 2026

Data Sources Report a data error